In a final draft guidance published today, the National Institute for Health and Care Excellence (NICE) has recommended relugolix-estradiol-norethisterone acetate (Ryeqo; Gedeon Ritcher UK) for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback